Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.67
AVEO's Cash-to-Debt is ranked lower than
74% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. AVEO: 1.67 )
Ranked among companies with meaningful Cash-to-Debt only.
AVEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54  Med: 3.85 Max: 9.15
Current: 1.67
1.54
9.15
Equity-to-Asset -0.07
AVEO's Equity-to-Asset is ranked lower than
93% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AVEO: -0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
AVEO' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.21  Med: 0.36 Max: 0.76
Current: -0.07
-3.21
0.76
Altman Z-Score: -27.62
Beneish M-Score: 0.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1168.35
AVEO's Operating Margin % is ranked lower than
78% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. AVEO: -1168.35 )
Ranked among companies with meaningful Operating Margin % only.
AVEO' s Operating Margin % Range Over the Past 10 Years
Min: -8035.89  Med: -211.41 Max: 20.59
Current: -1168.35
-8035.89
20.59
Net Margin % -1069.07
AVEO's Net Margin % is ranked lower than
78% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. AVEO: -1069.07 )
Ranked among companies with meaningful Net Margin % only.
AVEO' s Net Margin % Range Over the Past 10 Years
Min: -8277.57  Med: -219.61 Max: 18.59
Current: -1069.07
-8277.57
18.59
ROE % -362.90
AVEO's ROE % is ranked lower than
95% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. AVEO: -362.90 )
Ranked among companies with meaningful ROE % only.
AVEO' s ROE % Range Over the Past 10 Years
Min: -362.9  Med: -96.32 Max: 20.76
Current: -362.9
-362.9
20.76
ROA % -76.19
AVEO's ROA % is ranked lower than
80% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. AVEO: -76.19 )
Ranked among companies with meaningful ROA % only.
AVEO' s ROA % Range Over the Past 10 Years
Min: -88.25  Med: -52.18 Max: 13.74
Current: -76.19
-88.25
13.74
ROC (Joel Greenblatt) % -29434.87
AVEO's ROC (Joel Greenblatt) % is ranked lower than
94% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. AVEO: -29434.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -255591.3  Med: -791.02 Max: 689.47
Current: -29434.87
-255591.3
689.47
3-Year Revenue Growth Rate 12.90
AVEO's 3-Year Revenue Growth Rate is ranked higher than
63% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. AVEO: 12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVEO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -67.4 Max: 12.9
Current: 12.9
0
12.9
3-Year EBITDA Growth Rate -40.00
AVEO's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. AVEO: -40.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AVEO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -63.15 Max: -2.4
Current: -40
3-Year EPS without NRI Growth Rate -42.90
AVEO's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. AVEO: -42.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVEO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -53.7 Max: -3
Current: -42.9
GuruFocus has detected 2 Warning Signs with AVEO Pharmaceuticals Inc $AVEO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVEO's 10-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AVEO Guru Trades in Q1 2016

Jim Simons 2,094,900 sh (+6.02%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q2 2016

AVEO Guru Trades in Q2 2016

Jim Simons 2,405,400 sh (+14.82%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q3 2016

AVEO Guru Trades in Q3 2016

Jim Simons 2,595,400 sh (+7.90%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q4 2016

AVEO Guru Trades in Q4 2016

Jim Simons 2,743,900 sh (+5.72%)
Paul Tudor Jones 83,869 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:LPTX, NAS:CAPR, AMEX:SYN, NAS:EIGR, NAS:ALDX, NAS:KMPH, OTCPK:CWBR, OTCPK:PMCB, NAS:IPCI, NAS:GTXI, NAS:AQB, NAS:ZSAN, NAS:DRNA, NAS:CXRX, OTCPK:TBQBF, OTCPK:CNNRF, OTCPK:BLEVF, NAS:GLMD, OTCPK:ONCYF, OTCPK:ARTH » details
Traded in other countries:VPA.Germany,
Headquarter Location:USA
AVEO Pharmaceuticals Inc is a biopharmaceutical company. It is involved in discovering, developing and commercializing novel cancer therapeutics.

AVEO Pharmaceuticals is a biopharmaceutical company focused on novel cancer therapeutics. Its product candidates are directed against cancer-causing mechanisms found from its own laboratory research as well as general studies. Tivozanib, its main drug candidate, which is currently in a Phase 3 clinical trial, acts as a potent and selective oral inhibitor of vascular growth receptors.

Ratios

vs
industry
vs
history
PS Ratio 15.38
AVEO's PS Ratio is ranked lower than
56% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. AVEO: 15.38 )
Ranked among companies with meaningful PS Ratio only.
AVEO' s PS Ratio Range Over the Past 10 Years
Min: 0.63  Med: 4.76 Max: 101.25
Current: 15.38
0.63
101.25
EV-to-EBIT -1.95
AVEO's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AVEO: -1.95 )
Ranked among companies with meaningful EV-to-EBIT only.
AVEO' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.1  Med: -1.4 Max: 15
Current: -1.95
-8.1
15
EV-to-EBITDA -1.95
AVEO's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AVEO: -1.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVEO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.9  Med: -1.4 Max: 14.3
Current: -1.95
-15.9
14.3
Current Ratio 2.54
AVEO's Current Ratio is ranked lower than
66% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AVEO: 2.54 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.15 Max: 6.77
Current: 2.54
1.47
6.77
Quick Ratio 2.54
AVEO's Quick Ratio is ranked lower than
63% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AVEO: 2.54 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.15 Max: 6.77
Current: 2.54
1.47
6.77
Days Sales Outstanding 149.05
AVEO's Days Sales Outstanding is ranked lower than
84% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. AVEO: 149.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.19  Med: 42.9 Max: 390.8
Current: 149.05
3.19
390.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
AVEO's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. AVEO: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.9  Med: -9.9 Max: 0
Current: -13.6
-13.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 3.33
AVEO's Price-to-Median-PS-Value is ranked lower than
90% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AVEO: 3.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVEO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.07 Max: 15.25
Current: 3.33
0.51
15.25
Earnings Yield (Greenblatt) % -51.28
AVEO's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AVEO: -51.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVEO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -51.28  Med: 164.4 Max: 48140
Current: -51.28
-51.28
48140

More Statistics

Revenue (TTM) (Mil) $2.52
EPS (TTM) $ -0.40
Beta1.61
Short Percentage of Float1.09%
52-Week Range $0.50 - 1.15
Shares Outstanding (Mil)110.36
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO Pharmaceuticals (AVEO) Down 17.4% Since Earnings Report: Can It Rebound? Apr 24 2017
AVEO Announces Presentations at the 2017 ASCO Annual Meeting Apr 20 2017
AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List... Apr 13 2017
AVEO Announces Milestone Payment from CANbridge for AV-203 Apr 03 2017
AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Mar 31 2017
GGP, CenturyLink Drop into Tuesday’s 52-Week Low Club Mar 28 2017
AVEO Announces Pricing of $15.0 Million Public Offering of Common Stock Mar 28 2017
AVEO Announces Proposed Offering of Common Stock Mar 28 2017
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4 Mar 23 2017
AVEO reports 4Q loss Mar 22 2017
AVEO Reports Full Year 2016 Financial Results and Provides Business Update Mar 22 2017
AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab)... Mar 22 2017
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store? Mar 06 2017
Aveo Cancer Drug Tivozanib Clears Safety Review Feb 24 2017
AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review Feb 23 2017
AVEO Announces Clinical and Regulatory Updates for Tivozanib Feb 09 2017
AVEO to Present at the 19th Annual BIO CEO & Investor Conference Feb 06 2017
ETFs with exposure to AVEO Pharmaceuticals, Inc. : December 22, 2016 Dec 22 2016
How AVEO Pharmaceuticals, Inc. (AVEO) Stacks Up Against Its Peers? Dec 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)